Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-23-014914
Filing Date
2023-04-27
Accepted
2023-04-26 17:32:50
Documents
6
Period of Report
2023-06-08

Document Format Files

Seq Description Document Type Size
1 DEF 14A ovid_def_14a.htm DEF 14A 1205177
2 GRAPHIC img216885607_0.jpg GRAPHIC 242993
3 GRAPHIC img216885607_1.jpg GRAPHIC 18190
4 GRAPHIC img216885607_2.jpg GRAPHIC 13348
5 GRAPHIC img216885607_3.jpg GRAPHIC 1456235
6 GRAPHIC img216885607_4.jpg GRAPHIC 948520
  Complete submission text file 0000950170-23-014914.txt   4885475
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38085 | Film No.: 23851000
SIC: 2834 Pharmaceutical Preparations